Herein, presented the final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon
📌 3 Key Takeaways
🎯
Objective & Hypothesis:A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen (PSMA) treatment; however, his disease progressed.
📊
Key Findings & Data:A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen (PSMA) treatment; however, his disease progressed.
💡
Conclusion & Impact:Herein, presented the final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen (PSMA) treatment; however, his disease progressed. Herein, presented the final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon
Özet
Altmış dört yaşında erkek hasta metastatik prostat karsinomu tanısıyla lutesyum-177 prostat spesifik membran antijeni (PSMA) tedavisi almış ancak hastalığı progresyon göstermiştir. Bu sunumda bu hastanın nadir bir fenomen olan superscan görünümü oluşturan Galyum-68 PSMA pozitron emisyon tomografisi/bilgisayarlı tomografi görüntülerini paylaşmak istiyoruz.
🔖
Cite This Article
Reyhan, M., Erçolak, V., Koç, Z. P., Özcan, P. P. (2022). Superscan Appearance of 68Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer. Molecular Imaging and Radionuclide Therapy, Cilt: 31 - Sayı: 1, 60–62. https://ajindex.com/articles/425695
Kim SE, Kim DY, Lee DS, Chung JK, Lee MC, Koh CS. Absent or faint renal uptake on bone scan. Etiology and significance in metastatic bone disease. Clin Nucl Med 1991;16:545-549
Kim DW, Kim CG, Park SA, Jung SA, Yang SH. Metabolic super scan in F-FDG PET/CT imaging. J Korean Med Sci 2010;25:1256-1257 3. Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S. 18F-FDG PET/CT superscan in prostate cancer. Clin Nucl Med 2014;39:912-914
Parida GK, Soundararajan R, Passah A, Bal C, Kumar R. Metabolic Skeletal superscan on 18F-FDG PET/CT in a case of acute lymphoblastic leukemia. Clin Nucl Med 2015;40:567-568
Grellier JF, Lussato D, Queneau M, Guernou M, Songy B. Secondary hyperparathyroidism with “superscan-like” hypermetabolic FDG PET/CT pattern. Clin Nucl Med 2015;40:888-889
Chan M, Schembri GP. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT “superscan” in metastatic pancreatic neuroendocrine tumor. Clin Nucl Med 2017;42:108-109
Tan TH, Wong TH, Hassan SZ, Lee BN. Unusual bone superscan, MIBG superscan, and 68Ga DOTATATE PET/CT in metastatic pheochromocytoma. Clin Nucl Med 2015;40:867-868
Agarwal KK, Tripathi M, Kumar R, Bal C. Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan. Indian J Nucl Med 2016;31:150-151